PORTLAND, Maine – MedRhythms, a digital therapeutics company that uses sensors, software and music to measure and improve walking, today announced the appointment of Sabrina Taylor, Ph.D., CCRP as Head of Clinical Trials. Dr. Taylor will oversee ongoing and future clinical trials for MedRhythms’ pipeline products at leading institutions across the country.
Dr. Taylor brings to MedRhythms more than 10 years of experience in neuroscience research. She was most recently Director of Clinical Studies for the Brain and Spinal Injury Center (BASIC) at the University of California San Francisco, based at Zuckerberg San Francisco General Hospital and Trauma Center. During her tenure as the Director of Clinical Studies at BASIC, Dr. Taylor led a clinical research consortium of more than 20 clinical trial sites, all Level 1 trauma centers, for several national, multi-center clinical research initiatives, including the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) network. Dr. Taylor was also a Research Coordinator in the Neurorehabilitation Laboratory at Spaulding Rehabilitation Hospital, one of the nation’s top rehabilitation centers, where she coordinated the Traumatic Brain Injury Model System (TBIMS) and other projects.
“I am delighted to welcome Sabrina, who brings to MedRhythms a decade of experience in clinical trials at leading institutions throughout the U.S. Her proven track record of success conducting clinical trials focused on neurologic injury is precisely what we need at this important stage in MedRhythms’ development, as we progress our lead candidate towards commercialization and advance our pipeline,” said Brian Harris, Chief Executive Officer & Co-Founder at MedRhythms. “I look forward to working with her and the rest of our team to build novel, next-generation digital therapeutics to make an impact in the lives of the patients we serve.”
“I am thrilled to be joining the MedRhythms team at this pivotal time as the company looks to advance evidence-based digital therapeutics to treat a range of neurologic injuries and diseases,” said Dr. Taylor. “This is a team of dedicated and passionate individuals, and I look forward to working with the team and relocating from San Francisco to Portland for this opportunity to advance a pipeline of prescription digital therapeutics that are backed by clinical evidence.”
MedRhythms is currently conducting a multi-site randomized controlled clinical trial for MR-001, the Company’s flagship prescription digital therapeutic for chronic stroke survivors with walking impairments, at some of the top rehabilitation hospitals in the country. MedRhythms is also conducting research for the Company’s pipeline products in other neurologic injuries and diseases, including Parkinson’s disease, acute stroke and multiple sclerosis. Recently, MedRhythms announced a partnership with Universal Music Group and an oversubscribed Series B financing round.
MedRhythms, a privately held company headquartered in Portland, ME, is a digital therapeutics company that uses sensors, music, and software to build evidence-based, neurologic interventions to measure and improve walking. MedRhythms is dedicated to developing direct stimulation digital therapeutics, meaning that each therapeutic provides, via prescription music, direct stimulation to enable the mechanism of action in each relevant population. The company has an active pipeline of prescription digital therapeutics targeting rehabilitation and prevention in areas of neurologic injury and disease. The MedRhythms team has extensive experience in rehabilitation techniques utilizing music. The company has roots as a therapy services company that launched out of Spaulding Rehabilitation Hospital, which the U.S. News & World Report named the No. 2 ranked rehabilitation hospital in the country.
This management commentary contains certain forward-looking statements and information relating to the company that are based on information available to us as of the date hereof. Statements that are not historical facts, including statements about the company’s beliefs, designs, anticipation, aims, goals, expectations and potential results are forward-looking statements. In addition, the words “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “plan,” “should,” “could,” and similar expressions, and their variations and negatives, as they relate to the company or the future performance of the company, are intended to identify forward-looking statements. Such forward looking statements involve known and unknown risks, uncertainties, assumptions and other important factors that could cause the company’s actual results, performance or achievements of results to differ materially from any future results, performance or achievements expressed or implied by such forward looking statements. This management commentary speaks only as of the date hereof and the company does not undertake any obligation to update this commentary in the future.